Current Portfolio

Mosanna Therapeutics

Mosanna Therapeutics is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Switzerland
Fund: LSP 7
Entry: 2024
Website: Mosanna Therapeutics

Responsible Partner

Daniela Begolo

Managing Director

About

News

October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Two Decades of Future Proofing Companies

What is a Private Equity Fund?

“Doing as We're Told Could've Cost EQT €50B”

Discover Our Latest Insights on ThinQ by EQT

Q3 Announcement 2025

Mosanna Therapeutics

Responsible Partner

Daniela Begolo

News

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction

EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

Get in touch

Get in touch